Launched the MACOVIA trial for COVID-19 induced ARDS and enrolled first patients ..
Launched the MATRICS-1 trial for trauma related inflammation and complications with UTHealth ..
Healios advancement of TREASURE trial (w/ Sakigakedesignation)..
Fast Track and RMAT designations granted by FDA for our Phase 3 Stroke program… Positive Scientific Advice from by EMA ..
Launch of (and continued enrollment in) MASTERS-2 trial ..
Expansion of contract manufacturing capabilities to include CMO sites in Europe and Japan ..
2018 Expansion of collaboration with Healios ..
Maintained healthy balance sheet; with recent financing of $57.6 million gross ..
Completion of enrollment in MUST-ARDS trial –and successful results ..
Fast Track and RMAT designation for ARDS program ..
Healios’ advancement of the ONE-BRIDGE study for ARDS and Orphan designation from PMDA ..
BARDA and CoronaWatch Task Force designation for MultiStem as a “Highly Relevant” therapeutic for COVID-19 Primary priorities for 2020 ..
Complete enrollment for TREASURE and ONE-BRIDGE studies (Healios trials in Japan ..
Advancement of MASTERS-2 Phase 3 program ..
Advancement of the Phase 2/3 pivotal MACOVIA trial..
Complete evaluation / implementation of key partnering initiatives ..
Continued advancement of key process development and manufacturing initiatives, & commercialization prep ..
Also GILLY BOY is going to get huge pressure from the institutional ownership after the nightmare of Hardy's public comments with Traub's recent departure, should be a big catalyst for the company GILLY BOY lacks execution ..GOOD LUCK LONGS